ESCORT-1st
ESCORT-1st is China's first-line immunotherapy trial for squamous oesophageal cancer, one of five that together made chemo-immunotherapy the global standard.
OS 15.3 vs 12.0 months (HR 0.70; JAMA 2021), confirmed at final analysis (2024). Camrelizumab is approved in China for ESCC; not approved in the US. ESCORT-NEO (2024) showed neoadjuvant camrelizumab + chemotherapy raises pCR in resectable ESCC.
- Median 15.3 vs 12 months with Camrelizumab + chemotherapy compared with Placebo + chemotherapy; about 3.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 30 percent lower chance of the event at any given time (hazard ratio 0.7).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: First-line advanced oesophageal squamous cell carcinoma (China): camrelizumab + paclitaxel/cisplatin vs placebo + chemotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
596 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Camrelizumab + chemotherapy | 298 | 15.3 months | 0.7 | — | link |
| Placebo + chemotherapy | 298 | 12 months |
Pages like this
not linked directly; found by shared links- TrialRATIONALE-306
Shares Oesophageal cancer, PD-1.
- ProductToripalimab
Shares Rui-Hua Xu, Oesophageal cancer, PD-1.
- TrialKEYNOTE-590
Shares Oesophageal cancer, PD-1.
- PersonWenfeng Fang
Shares Camrelizumab, PD-1.
- TrialCheckMate 648
Shares Oesophageal cancer, PD-1.
- TrialCheckMate 577
Shares Oesophageal cancer, PD-1.
- PersonYelena Y. Janjigian
Shares Oesophageal cancer, PD-1.
- TrialHERIZON-GEA-01
Shares Oesophageal cancer, PD-1.